Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

BACKGROUND: Pragmatic use of the anti-fibrotic medications pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF) in the United States (US) has not been studied and may be different from international settings due to structural differences between health care systems. This study examined...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Respir Res
Autori principali: Holtze, Colin H., Freiheit, Elizabeth A., Limb, Susan L., Stauffer, John L., Raimundo, Karina, Pan, Wayne T., Flaherty, Kevin R., Kim, Hyun J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7011239/
https://ncbi.nlm.nih.gov/pubmed/32041621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-020-1315-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi